GlassScriptPhysician profile
Frank Taylor Wootton
NPI 1750366761
$5,804.47
in general payments reported to CMS, 2019-2025
42 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $189 · 2022: $421 · 2023: $976 · 2024: $1,466 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121 · Education: $52.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,121.00 |
| Education | $52.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,280.82 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Gilead Sciences, INC. | $618.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $492.75 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $429.40 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.17 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Regeneron Healthcare Solutions, INC. | $307.27 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $221.67 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $184.59 | 2023-2025 | Ibsrela |
| Medtronic, INC. | $175.24 | 2023-2025 | Gi Genius, Sharkcore, Barrx |
| Qol Medical, LLC | $162.16 | 2019-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $125.56 | 2020-2024 | Injectafer |
| Janssen Scientific Affairs, LLC | $124.20 | 2019 | |
| Celgene Corporation | $100.35 | 2023-2024 | Zeposia |
| Braintree Laboratories, INC. | $98.43 | 2019-2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $96.71 | 2019-2023 | Dificid |
Show all 39 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Wootton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.